Who are Pegylated liposomal doxorubicin hydrochloride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cipro, Epirubicin (E), Liposomal daunorubicin, epirubicin - cyclophosphamide / docetaxel + bevacizumab, Daunorubicin or Idarubicin, Epirubicin Injectable Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pegylated-liposomal-doxorubicin-hydrochloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Pegylated liposomal doxorubicin hydrochloride — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pegylated liposomal doxorubicin hydrochloride (Pegylated liposomal doxorubicin hydrochloride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anthracycline chemotherapy (liposomal formulation). Area: Oncology.

marketed Anthracycline chemotherapy (liposomal formulation) Topoisomerase II, DNA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pegylated liposomal doxorubicin hydrochloride (Pegylated liposomal doxorubicin hydrochloride) — M.D. Anderson Cancer Center. Pegylated liposomal doxorubicin delivers the chemotherapy agent doxorubicin encapsulated in liposomes coated with polyethylene glycol, which intercalates into DNA and inhibits topoisomerase II while reducing cardiotoxicity through prolonged circulation and selective tumor accumulation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pegylated liposomal doxorubicin hydrochloride TARGET	Pegylated liposomal doxorubicin hydrochloride	M.D. Anderson Cancer Center	marketed	Anthracycline chemotherapy (liposomal formulation)	Topoisomerase II, DNA
Cipro	ciprofloxacin	Bayer AG	marketed	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Epirubicin (E)	Epirubicin (E)	Eye & ENT Hospital of Fudan University	marketed	Anthracycline topoisomerase II inhibitor	Topoisomerase II, DNA
Liposomal daunorubicin	Liposomal daunorubicin	University of Birmingham	phase 3	Anthracycline chemotherapy agent	Topoisomerase II, DNA
epirubicin - cyclophosphamide / docetaxel + bevacizumab	epirubicin - cyclophosphamide / docetaxel + bevacizumab	GBG Forschungs GmbH	phase 3	anthracycline antibiotic, alkylating agent, taxane, monoclonal antibody	topoisomerase II, DNA, microtubules, VEGF
Daunorubicin or Idarubicin	Daunorubicin or Idarubicin	Stichting Hemato-Oncologie voor Volwassenen Nederland	phase 3	Anthracycline topoisomerase II inhibitor	Topoisomerase II, DNA
Epirubicin Injectable Product	Epirubicin Injectable Product	The First Affiliated Hospital with Nanjing Medical University	phase 3	Anthracycline topoisomerase II inhibitor	Topoisomerase II, DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-04-21 — Cipro · 11369566 · Formulation · US
2029-04-21 — Cipro · 9603796 · Compound · US
2029-04-21 — Cipro · 9205048 · Method of Use · US
2029-12-11 — Cipro · 9233068 · Formulation · US
2030-04-27 — Cipro · 8318817 · Method of Use · US
2035-07-01 — Cipro · 9220796 · Formulation · US
2037-11-12 — Cipro · 11040004 · Method of Use · US
2038-11-27 — Cipro · 11246863 · Formulation · US

Sponsor landscape (Anthracycline chemotherapy (liposomal formulation) class)

M.D. Anderson Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pegylated liposomal doxorubicin hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/pegylated-liposomal-doxorubicin-hydrochloride. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab